Operation Brain Trauma Therapy: 2016 Update

Area of Science:

• Neuroscience
• Pharmacology
• Biomarker Research

Background:

• Traumatic brain injury (TBI) presents complex challenges for effective treatment development.
• Existing pre-clinical models often fail to predict clinical efficacy, necessitating robust screening platforms.
• Operation Brain Trauma Therapy (OBTT) is a consortium designed to address these limitations through multi-center drug and biomarker screening.

Purpose of the Study:

• To evaluate the efficacy of novel therapies across diverse TBI models.
• To identify potential TBI biomarkers that predict therapeutic response.
• To guide the selection of therapies for future clinical trials based on pre-clinical data.

Main Methods:

• Screening of multiple drug candidates (e.g., levetiracetam, glibenclamide, amantadine) in three distinct rat TBI models: parasagittal fluid percussion injury, controlled cortical impact (CCI), and penetrating ballistic-like brain injury.
• Assessment of therapeutic effects on cognitive outcomes, histology, and protein biomarkers.
• Analysis of glial fibrillary acidic protein (GFAP) levels as a predictive biomarker for treatment response.

Main Results:

• Levetiracetam demonstrated benefits in cognitive outcomes, histology, and biomarkers across two TBI models.
• Glibenclamide showed significant improvements in motor function and histology in the CCI model.
• Amantadine and cyclosporine (CsA) exhibited model-dependent therapeutic effects, highlighting the need for phenotype-specific approaches.
• Elevated glial fibrillary acidic protein (GFAP) levels were found to predict treatment efficacy.

Conclusions:

• Levetiracetam warrants further pre-clinical and clinical investigation for TBI treatment.
• Glibenclamide and amantadine show potential for targeted application in specific TBI phenotypes.
• The OBTT consortium model proves effective in advancing TBI therapy and biomarker discovery, paving the way for precision medicine in TBI care.